In one notable case, a patient with metastatic GC experienced complete tumor regression sustained for 25 months following the first administration of a personalized neoantigen-loaded monocyte-derived DC vaccine (Neo-MoDC) in combination with PD - 1 blockade (60). This evidence concerns the gene RPL17 and gastric cancer.